Saturday, 31 October 2026European Markets

CAIRN HOMES PLC, CAFOM, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - cairn homes plc (c5h.ir) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
cairn homes plc (c5h.ir) €1.84 3.51% 11.32%
cafom (cafo.pa) €9.00 2.36% 6.66%
abeo (abeo.pa) €10.30 1.98% 1.84%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. cairn homes plc (c5h.ir)

3.51% forward dividend yield and 11.32% return on equity

cairn homes plc, a holding company, operates as a home and community builder in ireland. the company engages in the development and sale of residential properties, as well as rental of properties. it also provides financial services. cairn homes plc was incorporated in 2014 and is based in dublin, ireland.

earnings per share

as for profitability, cairn homes plc has a trailing twelve months eps of €0.13.

pe ratio

cairn homes plc has a trailing twelve months price to earnings ratio of 14.14. meaning, the purchaser of the share is investing €14.14 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.32%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, cairn homes plc's stock is considered to be overbought (>=80).

more news about cairn homes plc.

2. cafom (cafo.pa)

2.36% forward dividend yield and 6.66% return on equity

centrale d'achat française pour l'outre-mer société anonyme provides home furnishing products in south-east asia, south america, europe, and middle east. the company offers household appliance products and services under darty; home equipment under but; design manufacturing under habitat; natural and wellness products under the nature & discoveries; furniture, decoration, and appliances under but cosy; and musical instruments under the music & sound brands in guadeloupe, french guiana, martinique, saint-martin, reunion island, and new caledonia. it also operates vente-unique.com, a b2c platform that engages in the online sale of furniture for individuals; and directlowcost.com that supplies furniture and decoration products for distribution professionals. the company was founded in 1985 and is based in paris, france.

earnings per share

as for profitability, cafom has a trailing twelve months eps of €1.33.

pe ratio

cafom has a trailing twelve months price to earnings ratio of 6.77. meaning, the purchaser of the share is investing €6.77 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.66%.

volume

today's last reported volume for cafom is 815 which is 50.12% below its average volume of 1634.

more news about cafom.

3. abeo (abeo.pa)

1.98% forward dividend yield and 1.84% return on equity

abéo sa engages in the design, manufacture, and distribution of sports and leisure equipment in france and internationally. it offers gymnastics equipment and facilities, gym mats, team sports equipment, physical education, trampoline parks, and artificial climbing walls, as well as changing room layouts, cabins, cupboards, and lockers. it offers its products under the gymnova, janssen-fritsen, spieth gymnastics, schelde sports, spieth america, sportsafe, erhard sport, adec sport, o'jump, cannice, bosan, pcv, vogoscope, bigairbag, brick, ep, clip'n climb, top30, dock 39, fun spot, climbat, france equipement, meta, prospec, navic, sanitec, suffixe, and sanelite brands. the company was founded in 1955 and is headquartered in rioz, france.

earnings per share

as for profitability, abeo has a trailing twelve months eps of €0.34.

pe ratio

abeo has a trailing twelve months price to earnings ratio of 30.29. meaning, the purchaser of the share is investing €30.29 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.84%.

dividend yield

as stated by morningstar, inc., the next dividend payment is on jul 29, 2024, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 1.98%.

yearly top and bottom value

abeo's stock is valued at €10.30 at 22:30 est, way under its 52-week high of €18.30 and higher than its 52-week low of €9.82.

volume

today's last reported volume for abeo is 6 which is 99.41% below its average volume of 1032.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, abeo's stock is considered to be oversold (<=20).

more news about abeo.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com